BRD4 and colorectal carcinoma: BRD4 inhibition or degradation has shown synergistic activity with chemotherapy and immune checkpoint blockade in preclinical CRC models, supporting the view that BRD4 targeting might re-sensitize resistant tumors and modulate the immunosuppressive microenvironment.